imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
bortezomib actavis 3,5 mg prašak za otopinu za injekciju
actavis group ptc ehf., dalshraun 1, hafnarfjoerdur, island - бортезомиб - prašak za otopinu za injekciju - 3,5 mg - urbroj: jedna bočica sadrži 3,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola)
bortezomib alpha-medical 3,5 mg prašak za otopinu za injekciju
alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - бортезомиб - prašak za otopinu za injekciju - 3,5 mg - urbroj: svaka bočica sadrži 3,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola)
bortezomib pliva 2,5 mg prašak za otopinu za injekciju
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - бортезомиб - prašak za otopinu za injekciju - 2,5 mg - urbroj: jedna bočica sadrži 2,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola)
bortezomib mylan 1 mg prašak za otopinu za injekciju
mylan pharmaceuticals limited, damastown industrial park, mulhuddart, dublin, irska - бортезомиб - prašak za otopinu za injekciju - 1 mg - urbroj: jedna bočica sadrži 1 mg bortezomiba (u obliku estera boronatne kiseline i manitola)
bortezomib mylan 3,5 mg prašak za otopinu za injekciju
mylan pharmaceuticals limited, damastown industrial park, mulhuddart, dublin, irska - бортезомиб - prašak za otopinu za injekciju - 3,5 mg - urbroj: jedna bočica sadrži 3,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola)
gloftrinid 3,5 mg prašak za otopinu za injekciju
alkaloid - int d.o.o., Šlandrova ulica 4, ljubljana - Črnuče, slovenija - бортезомиб - prašak za otopinu za injekciju - 3,5 mg - urbroj: jedna bočica sadrži 3,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola).
bortezomib stada 2,5 mg/1 ml rastvor za injekciju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - bortezomib - rastvor za injekciju - 2,5 mg/1 ml - 1 ml rastvora za injekciju sadrži: 2,5 mg bortezomiba
bortezomib ever pharma 2,5 mg/ml otopina za injekciju
ever valinject gmbh, oberburgau 3, unterach am attersee, austrija - бортезомиб - otopina za injekciju - urbroj: 1 ml otopine za injekciju sadrži 2,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola) jedna bočica s 1 ml otopine za injekciju sadrži 2,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola) jedna bočica s 1,4 ml otopine za injekciju sadrži 3,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola)